Immediate development priorities are: (i) optimizing exposure–response to achieve deeper target engagement in AML; (ii) biomarker-driven selection for spliceosome-mutant and DCAF15-high subgroups; and (iii) embedding mechanism-orthogonal partners (e.g., venetoclax, ATR/WEE1 inhibitors) to translate splicing stress into durable cytoreduction (Lachowiez et al., 2021). This evidence concerns the gene ATR and acute myeloid leukemia.